Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cytotoxic T Cell Therapy for Post Transplant Lymphoproliferative Disease
NCT00033475Phase 3Completed
- Sponsor
- University of Edinburgh
- Start
- Mar 2001
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
A Phase 3 trial of therapeutic allogeneic lymphocytes in Post-transplant lymphoproliferative disease (PTLD), sponsored by University of Edinburgh. Started Mar 2001; status: completed.
02
Drugs
therapeutic allogeneic lymphocytes
03
Conditions
Post-transplant lymphoproliferative disease (PTLD)
Beyond the preview
Go deeper on NCT00033475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00033475.